Non-small cell lung cancer
Verastem Inc. supports clinical research in non-small cell lung cancer with a focus on targeted treatment strategies for tumors carrying G12C alterations. The sponsor’s studies examine combinations centered on avutometinib and sotorasib in patients with advanced lung cancer.
- Targeted therapy
- Oncogenic KRAS pathway inhibition
- Combination treatment in lung cancer
The research activity reflects sustained interest in molecularly defined thoracic oncology and treatment options for KRAS G12C-mutant disease.
Recurrent low-grade serous ovarian cancer
The sponsor is actively involved in studies for recurrent low-grade serous ovarian cancer, a distinct subtype of ovarian cancer with specialized therapeutic needs. Its trials evaluate avutometinib alone and in combination with defactinib in this setting.
- Recurrent ovarian cancer
- MAPK pathway-directed treatment
- Combination therapy for LGSOC
Clinical research in this area centers on treatment approaches for patients with persistent disease after prior therapy, with attention to low-grade serous histology.
Signal transduction and pathway-targeted oncology
Verastem Inc. funds research in signal transduction-focused oncology, particularly therapies that act on the RAF-MEK-ERK and FAK pathways. This includes investigation of avutometinib as a backbone treatment in both lung and ovarian cancer studies.
- MEK inhibition
- FAK inhibition
- Pathway-based cancer treatment
The sponsor’s portfolio links molecular pathway targeting with disease-specific oncology programs in solid tumors.
Combination oncology regimens
Several of the sponsor’s trials explore combination therapy strategies intended to improve outcomes in difficult-to-treat cancers. These studies pair avutometinib with agents such as sotorasib or defactinib across lung cancer and ovarian cancer indications.
- Dual-agent regimens
- Targeted oncology combinations
- Precision medicine in solid tumors
This research area emphasizes therapeutic combinations designed for mutation-defined and histology-specific cancer populations.
